Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

GMGiovanni MarsiliPFPaola FaziMTMario Tiribelli

Discussion

Loading...

Member takes

Overview

Non-randomized trial finds venetoclax and azacitidine improve outcomes in acute myeloid leukemia, suggesting effective bridge-to-transplant strategies.

Key Points

  • Venetoclax and azacitidine treatment shows 80% of patients achieved molecular negativity in acute myeloid leukemia.
  • Overall response rate recorded was 86%, with 24 of 25 patients maintaining complete remission during the trial.
  • The GIMEMA AML2521 trial explores an innovative therapy approach for high-risk acute myeloid leukemia patients.
  • Results indicate potential for bridging patients to allogeneic stem cell transplantation safely and effectively.

Cite This Study

Marsili et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e562https://doi.org/10.1182/blood-2025-3516
View Full Paper
Ask AI
Bookmark
Share